Novo Nordisk takes Dr. Reddy’s to court over Ozempic-like brand name
With semaglutide off-patent, a flood of low-cost generics is shifting the fight from molecules to brand names in India’s fast-growing weight-loss market
With semaglutide off-patent, a flood of low-cost generics is shifting the fight from molecules to brand names in India’s fast-growing weight-loss market
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
